
Allurion Technologies (ALUR) Stock
Allurion Technologies Chart
Company Profile
Price: $5.15
Market Cap: $24.68M
Exchange: NYSE
CEO: Dr. Shantanu K. Gaur M.D.
Sector: Healthcare
Industry: Medical - Devices
Employees: 501
Headquarters: Natick, MA
Website: Allurion Technologies
Business Summary
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Allurion Technologies News
Allurion Relaunches in France
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. “We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “Historically, France has been.

How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%
The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company's common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules. In addition, in a concurrent private placement, the Compan.

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous.

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion's proprietary Balloon technology and the introduction of in.

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company's common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Compa.

Allurion Technologies, Inc. Announces Reverse Stock Split
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis.

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the “Minimum Market Capitalization Standard”.

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company's AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the.

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executive Officer Brian Conyer – Vice President-Digital Health Adrian Wild – Senior Vice President-International Commercial Chris Geberth – Chief Financial Officer Conference Call Participants Josh Jennings – TD Cowen Matt Taylor – Jefferies Operator Thank you for standing by. My name is John, and I'll be your conference operator today.

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (int.

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduc.

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q2 2024 Earnings Call Transcript August 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Shantanu Gaur - Founder and CEO Chris Geberth - CFO Conference Call Participants Keay Nakae - Chardan Matt Taylor - Jefferies Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.

Allurion Announces Launch of Offering of Common Stock and Warrants
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.

Why Is Allurion (ALUR) Stock Up 140% Today?
Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name.

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite. In the st.

Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024. Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison,.

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working.

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1.

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change program. This study was cond.

Allurion Technologies Earnings
This section highlights Allurion Technologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q3 | 2024 | 2024-11-13 | $-4.25 | $-3.50 |
Read Transcript | Q2 | 2024 | 2024-08-13 | $-0.24 | $0.25 |
Read Transcript | Q1 | 2024 | 2024-05-14 | $-0.30 | $2.75 |
Read Transcript | Q4 | 2023 | 2024-03-21 | $-12.75 | $-15.75 |
Read Transcript | Q3 | 2023 | 2023-11-17 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Allurion Technologies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Revenue | $53.47M | $64.21M | $38.24M | $- |
Cost of Revenue | $11.97M | $13.48M | $9.05M | $- |
Gross Profit | $41.50M | $50.73M | $29.19M | $- |
Gross Profit Ratio | 77.61% | 79.00% | 76.33% | 0.00% |
Research and Development Expenses | $27.69M | $16.97M | $5.73M | $- |
General and Administrative Expenses | $46.02M | $15.37M | $8.82M | $- |
Selling and Marketing Expenses | $46.86M | $50.41M | $27.14M | $- |
Selling General and Administrative Expenses | $92.88M | $65.77M | $35.96M | $4.56K |
Other Expenses | $- | $-1.15M | $-555.00K | $-610 |
Operating Expenses | $120.58M | $82.74M | $41.69M | $5.17K |
Cost and Expenses | $132.54M | $96.22M | $50.74M | $5.17K |
Interest Income | $- | $10.66M | $49.77K | $- |
Interest Expense | $10.57M | $4.43M | $3.67M | $- |
Depreciation and Amortization | $746.00K | $895.00K | $707.00K | $206.30K |
EBITDA | $-69.03M | $-32.28M | $-12.35M | $-5.17K |
EBITDA Ratio | -129.11% | -48.52% | -32.29% | 0.00% |
Operating Income | $-79.08M | $-32.01M | $-12.50M | $-5.17K |
Operating Income Ratio | -147.90% | -49.85% | -32.69% | 0.00% |
Total Other Income Expenses Net | $-1.26M | $-5.59M | $115.00K | $1 |
Income Before Tax | $-80.34M | $-37.60M | $-12.39M | $-5.17K |
Income Before Tax Ratio | -150.27% | -58.56% | -32.39% | 0.00% |
Income Tax Expense | $264.00K | $143.00K | $3.11M | $-206.30K |
Net Income | $-82.30M | $-37.74M | $-12.39M | $-5.17K |
Net Income Ratio | -153.93% | -58.78% | -32.39% | 0.00% |
EPS | $-2.31 | $-1.40 | $-0.11 | $0.00 |
EPS Diluted | $-2.31 | $-1.40 | $-0.11 | $0.00 |
Weighted Average Shares Outstanding | 35.58M | 26.92M | 107.81M | 107.81M |
Weighted Average Shares Outstanding Diluted | 35.58M | 26.92M | 107.81M | 107.81M |
SEC Filing | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $5.37M | $11.77M | $9.39M | $8.23M | $18.20M | $12.96M | $14.07M | $19.18M | $16.06M | $16.25M | $12.71M | $- | $- | $- | $- |
Cost of Revenue | $2.26M | $2.77M | $2.69M | $1.91M | $4.23M | $2.99M | $2.94M | $3.94M | $3.47M | $3.50M | $2.58M | $- | $- | $- | $- |
Gross Profit | $3.11M | $8.99M | $6.70M | $6.33M | $13.97M | $9.97M | $11.13M | $15.24M | $12.59M | $12.76M | $10.14M | $- | $- | $- | $- |
Gross Profit Ratio | 57.97% | 76.43% | 71.38% | 76.85% | 76.75% | 76.91% | 79.11% | 79.46% | 78.37% | 78.49% | 79.74% | 0.00% | 0.00% | 0.00% | 0.00% |
Research and Development Expenses | $3.21M | $4.26M | $5.68M | $6.02M | $7.19M | $6.58M | $7.85M | $5.73M | $5.07M | $3.10M | $3.07M | $- | $- | $- | $- |
General and Administrative Expenses | $7.04M | $7.31M | $6.39M | $15.37M | $18.94M | $6.41M | $5.31M | $4.72M | $3.82M | $3.05M | $3.78M | $- | $- | $- | $- |
Selling and Marketing Expenses | $5.20M | $6.72M | $6.14M | $10.73M | $13.99M | $10.27M | $11.86M | $14.94M | $15.69M | $10.90M | $8.87M | $- | $- | $- | $- |
Selling General and Administrative Expenses | $12.24M | $14.03M | $12.31M | $26.04M | $32.93M | $16.68M | $17.17M | $19.66M | $19.51M | $13.95M | $12.65M | $603.98K | $419.77K | $663.77K | $343.74K |
Other Expenses | $- | $- | $172.00K | $-776.00K | $389.00K | $-85.00K | $-135.00K | $-272.00K | $-420.00K | $-287.00K | $-167.00K | $-52.60K | $-49.86K | $-49.32K | $-48.27K |
Operating Expenses | $15.45M | $18.15M | $17.99M | $32.07M | $40.12M | $23.26M | $25.02M | $25.39M | $24.57M | $17.05M | $15.72M | $656.58K | $469.63K | $713.10K | $392.00K |
Cost and Expenses | $17.71M | $21.11M | $20.68M | $33.97M | $44.35M | $26.25M | $27.96M | $29.33M | $28.05M | $20.54M | $18.30M | $656.58K | $469.63K | $713.09K | $392.01K |
Interest Income | $- | $- | $- | $- | $- | $- | $1.01M | $5.47M | $3.90M | $- | $- | $16.36K | $13.25K | $13.11K | $7.06K |
Interest Expense | $- | $339.00K | $1.93M | $3.23M | $2.59M | $2.51M | $2.24M | $1.76M | $1.14M | $825.00K | $702.00K | $- | $- | $- | $- |
Depreciation and Amortization | $214.00K | $197.00K | $367.00K | $188.00K | $160.00K | $154.00K | $245.00K | $1.35M | $229.00K | $210.00K | $213.00K | $- | $- | $- | $- |
EBITDA | $-12.34M | $-1.56M | $7.96M | $-15.58M | $-18.85M | $-19.31M | $-15.29M | $-9.19M | $-12.11M | $-4.37M | $-5.50M | $2.45M | $19.18M | $-10.69M | $-5.18M |
EBITDA Ratio | -229.94% | -13.27% | -116.38% | -310.26% | -141.57% | -102.04% | -97.94% | -47.29% | -75.80% | -26.89% | -43.56% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | $-12.34M | $-9.25M | $-11.29M | $-25.74M | $-26.15M | $-13.29M | $-13.89M | $-10.15M | $-11.98M | $-4.29M | $-5.58M | $-656.58K | $-469.63K | $-713.10K | $-392.00K |
Operating Income Ratio | -229.94% | -78.58% | -120.29% | -312.54% | -143.70% | -102.58% | -98.72% | -52.90% | -74.61% | -26.42% | -43.92% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income Expenses Net | $3.41M | $7.15M | $-5.73M | $6.73M | $4.56M | $-8.68M | $-3.88M | $-2.15M | $-1.49M | $-1.11M | $-835.00K | $3.10M | $19.65M | $-9.97M | $-4.79M |
Income Before Tax | $-8.94M | $-2.10M | $5.66M | $-19.01M | $-21.60M | $-21.97M | $-17.77M | $-12.30M | $-13.48M | $-5.41M | $-6.42M | $2.45M | $19.18M | $-10.69M | $-5.18M |
Income Before Tax Ratio | -166.48% | -17.82% | 60.32% | -230.80% | -118.66% | -169.55% | -126.27% | -64.12% | -83.90% | -33.26% | -50.49% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | $69.00K | $65.00K | $76.00K | $174.00K | $34.00K | $22.00K | $34.00K | $48.00K | $95.00K | $538.00K | $535.00K | $- | $- | $- | $- |
Net Income | $-9.00M | $-2.16M | $5.59M | $-19.18M | $-21.63M | $-22.00M | $-17.80M | $-12.35M | $-13.57M | $-5.41M | $-6.42M | $2.45M | $19.18M | $-10.69M | $-5.18M |
Net Income Ratio | -167.77% | -18.37% | 59.51% | -232.91% | -118.85% | -169.72% | -126.51% | -64.37% | -84.49% | -33.26% | -50.49% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | $-0.14 | $-0.05 | $0.12 | $-0.40 | $-0.54 | $-2.86 | $-0.58 | $-0.11 | $-0.29 | $-0.12 | $-0.14 | $0.02 | $0.18 | $-0.10 | $-0.05 |
EPS Diluted | $-0.14 | $-0.05 | $0.11 | $-0.40 | $-0.54 | $-2.86 | $-0.58 | $-0.11 | $-0.29 | $-0.12 | $-0.14 | $0.02 | $0.18 | $-0.10 | $-0.05 |
Weighted Average Shares Outstanding | 64.09M | 47.95M | 47.78M | 47.52M | 40.34M | 7.68M | 30.79M | 107.81M | 46.50M | 46.50M | 46.50M | 107.81M | 107.81M | 107.81M | 107.81M |
Weighted Average Shares Outstanding Diluted | 64.09M | 47.95M | 49.19M | 47.52M | 40.34M | 7.68M | 30.79M | 107.81M | 46.50M | 46.50M | 46.50M | 107.81M | 107.81M | 107.81M | 107.81M |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Cash and Cash Equivalents | $38.04M | $7.68M | $25.84M | $47.09K |
Short Term Investments | $- | $- | $- | $- |
Cash and Short Term Investments | $38.04M | $7.68M | $25.84M | $47.09K |
Net Receivables | $18.19M | $29.35M | $6.83M | $- |
Inventory | $6.17M | $3.87M | $2.71M | $- |
Other Current Assets | $2.41M | $2.49M | $1.94M | $- |
Total Current Assets | $64.82M | $43.38M | $37.33M | $47.09K |
Property Plant Equipment Net | $6.39M | $5.28M | $1.71M | $- |
Goodwill | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- |
Long Term Investments | $384.00K | $94.33M | $862.55M | $- |
Tax Assets | $- | $- | $- | $- |
Other Non-Current Assets | $121.00K | $-91.62M | $-862.24M | $282.88K |
Total Non-Current Assets | $6.90M | $7.99M | $2.02M | $282.88K |
Other Assets | $- | $- | $- | $- |
Total Assets | $71.71M | $51.37M | $39.35M | $329.96K |
Account Payables | $10.38M | $5.81M | $1.62M | $- |
Short Term Debt | $39.55M | $54.27M | $24.14M | $170.00K |
Tax Payables | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $202.00K | $- |
Other Current Liabilities | $15.49M | $15.79M | $5.65M | $140.13K |
Total Current Liabilities | $65.42M | $75.87M | $31.61M | $310.13K |
Long Term Debt | $2.31M | $5.27M | $2.00M | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
Other Non-Current Liabilities | $74.47M | $41.67M | $40.02M | $- |
Total Non-Current Liabilities | $76.77M | $46.94M | $42.02M | $- |
Other Liabilities | $- | $- | $- | $- |
Total Liabilities | $142.20M | $122.81M | $73.64M | $310.13K |
Preferred Stock | $- | $58.00M | $57.97M | $- |
Common Stock | $5.00K | $51.00K | $51.00K | $2.16K |
Retained Earnings | $-212.80M | $-132.19M | $-94.45M | $-5.17K |
Accumulated Other Comprehensive Income Loss | $-700.00K | $- | $- | $- |
Other Total Stockholders Equity | $143.01M | $99.88M | $2.14M | $22.84K |
Total Stockholders Equity | $-70.49M | $-71.44M | $-34.28M | $19.83K |
Total Equity | $-70.49M | $-71.44M | $-34.28M | $19.83K |
Total Liabilities and Stockholders Equity | $71.71M | $51.37M | $39.35M | $329.96K |
Minority Interest | $- | $- | $- | $- |
Total Liabilities and Total Equity | $71.71M | $51.37M | $39.35M | $329.96K |
Total Investments | $384.00K | $94.33M | $862.55M | $- |
Total Debt | $41.86M | $59.53M | $26.14M | $170.00K |
Net Debt | $3.82M | $51.85M | $300.00K | $122.91K |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $28.65M | $19.26M | $29.68M | $38.04M | $79.87M | $4.74M | $9.94M | $7.68M | $1.01M | $66.79K | $272.50K | $836.87K | $958.65K | $1.07M | $68.28K |
Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $28.65M | $19.26M | $29.68M | $38.04M | $79.87M | $4.74M | $9.94M | $7.68M | $1.01M | $66.79K | $272.50K | $836.87K | $958.65K | $1.07M | $68.28K |
Net Receivables | $9.94M | $13.36M | $16.16M | $18.19M | $27.64M | $25.56M | $28.99M | $29.35M | $- | $- | $- | $- | $- | $- | $- |
Inventory | $4.57M | $4.79M | $5.63M | $6.17M | $4.02M | $4.86M | $4.31M | $3.87M | $- | $- | $- | $- | $- | $- | $- |
Other Current Assets | $1.67M | $2.90M | $2.17M | $2.41M | $2.29M | $1.91M | $2.48M | $2.49M | $270.88K | $470.61K | $670.33K | $774.68K | $948.97K | $1.13M | $1.32M |
Total Current Assets | $44.83M | $40.30M | $53.64M | $64.82M | $113.82M | $37.07M | $45.73M | $43.38M | $1.28M | $537.40K | $942.83K | $1.61M | $1.91M | $2.20M | $1.39M |
Property Plant Equipment Net | $5.36M | $5.74M | $5.84M | $6.39M | $6.52M | $5.91M | $6.15M | $5.28M | $- | $- | $- | $- | $- | $- | $- |
Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Long Term Investments | $- | $388.00K | $386.00K | $384.00K | $232.00K | $368.00K | $96.54M | $94.33M | $867.07M | $863.85M | $862.62M | $862.55M | $862.53M | $862.52M | $862.51M |
Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Assets | $507.00K | $122.00K | $124.00K | $121.00K | $122.00K | $8.80M | $-90.45M | $-91.62M | $- | $-1 | $- | $- | $- | $-1 | $- |
Total Non-Current Assets | $5.87M | $6.24M | $6.35M | $6.90M | $6.87M | $15.09M | $12.24M | $7.99M | $867.07M | $863.85M | $862.62M | $862.55M | $862.53M | $862.52M | $862.51M |
Other Assets | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $1 | $- |
Total Assets | $50.70M | $46.55M | $59.99M | $71.71M | $120.69M | $52.15M | $57.97M | $51.37M | $868.36M | $864.38M | $863.56M | $864.16M | $864.44M | $864.72M | $863.89M |
Account Payables | $10.39M | $7.98M | $11.94M | $10.38M | $9.36M | $14.77M | $13.71M | $5.81M | $- | $- | $- | $- | $- | $- | $- |
Short Term Debt | $878.00K | $1.70M | $40.59M | $40.46M | $59.42M | $55.35M | $54.39M | $54.27M | $913.52K | $- | $- | $- | $- | $- | $- |
Tax Payables | $- | $- | $- | $- | $- | $- | $27.15K | $- | $674.92K | $219.37K | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Current Liabilities | $7.97M | $13.87M | $13.69M | $14.59M | $18.44M | $19.77M | $15.86M | $15.79M | $59.37K | $32.89K | $78.43K | $371.01K | $968.10K | $791.37K | $763.28K |
Total Current Liabilities | $19.24M | $23.56M | $66.22M | $65.42M | $87.23M | $89.89M | $83.98M | $75.87M | $1.65M | $252.26K | $78.43K | $371.01K | $968.10K | $791.37K | $763.28K |
Long Term Debt | $37.67M | $42.74M | $2.01M | $2.31M | $2.51M | $22.61M | $19.61M | $5.27M | $- | $1.39M | $1.35M | $1.39M | $1.38M | $1.68M | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $58.58M | $50.84M | $57.92M | $74.47M | $83.70M | $50.00M | $43.16M | $41.67M | $34.73M | $39.23M | $48.37M | $61.41M | $63.55M | $82.90M | $73.09M |
Total Non-Current Liabilities | $96.25M | $93.57M | $59.93M | $76.77M | $86.22M | $72.61M | $62.76M | $46.94M | $34.73M | $40.62M | $49.72M | $62.81M | $64.94M | $84.58M | $73.09M |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $115.49M | $117.13M | $126.15M | $142.20M | $173.44M | $162.49M | $146.74M | $122.81M | $36.38M | $40.87M | $49.80M | $63.18M | $65.90M | $85.37M | $73.86M |
Preferred Stock | $- | $- | $- | $- | $- | $58.03M | $58.03M | $58.00M | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $7.00K | $5.00K | $5.00K | $5.00K | $5.00K | $51.00K | $51.00K | $51.00K | $866.27M | $863.23M | $862.50M | $862.50M | $862.50M | $774.35M | $785.04M |
Retained Earnings | $-218.38M | $-209.38M | $-207.21M | $-212.80M | $-193.62M | $-171.99M | $-149.99M | $-132.19M | $-34.29M | $-39.71M | $-48.74M | $-61.52M | $-63.97M | $-15.87M | $-5.19M |
Accumulated Other Comprehensive Income Loss | $2.89M | $-5.98M | $-2.90M | $-700.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Total Stockholders Equity | $151.67M | $144.77M | $143.95M | $143.01M | $140.86M | $3.56M | $3.13M | $218.32M | $- | $- | $- | $- | $- | $20.87M | $10.19M |
Total Stockholders Equity | $-63.81M | $-70.58M | $-66.16M | $-70.49M | $-52.76M | $-110.34M | $-88.78M | $-71.44M | $831.98M | $823.51M | $813.76M | $800.98M | $798.54M | $779.35M | $790.04M |
Total Equity | $-63.81M | $-70.58M | $-66.16M | $-70.49M | $-52.76M | $-110.34M | $-88.78M | $-71.44M | $831.98M | $823.51M | $813.76M | $800.98M | $798.54M | $779.35M | $790.04M |
Total Liabilities and Stockholders Equity | $50.70M | $46.55M | $59.99M | $71.71M | $120.69M | $52.15M | $57.97M | $51.37M | $868.36M | $864.38M | $863.56M | $864.16M | $864.44M | $864.72M | $863.89M |
Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $50.70M | $46.55M | $59.99M | $71.71M | $120.69M | $52.15M | $57.97M | $51.37M | $868.36M | $864.38M | $863.56M | $864.16M | $864.44M | $864.72M | $863.89M |
Total Investments | $- | $388.00K | $386.00K | $384.00K | $232.00K | $368.00K | $96.54M | $94.33M | $867.07M | $863.85M | $862.62M | $862.55M | $862.53M | $862.52M | $862.51M |
Total Debt | $38.55M | $43.59M | $41.78M | $41.86M | $61.06M | $77.12M | $73.99M | $59.53M | $913.52K | $1.39M | $1.35M | $1.39M | $1.38M | $1.68M | $- |
Net Debt | $9.89M | $24.33M | $12.10M | $3.82M | $-18.80M | $72.38M | $64.05M | $51.85M | $-99.88K | $1.32M | $1.08M | $556.08K | $426.32K | $608.13K | $-68.28K |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Net Income | $-80.61M | $-37.74M | $-12.39M | $-5.17K |
Depreciation and Amortization | $746.00K | $2.00M | $707.00K | $- |
Deferred Income Tax | $- | $1.27M | $665.00K | $- |
Stock Based Compensation | $8.36M | $437.00K | $313.00K | $- |
Change in Working Capital | $194.00K | $-13.79M | $-1.27M | $5.13K |
Accounts Receivables | $-1.32M | $-22.82M | $-707.00K | $- |
Inventory | $-3.71M | $-1.15M | $-1.28M | $- |
Accounts Payables | $4.66M | $3.32M | $-488.00K | $- |
Other Working Capital | $553.00K | $6.86M | $1.21M | $5.13K |
Other Non Cash Items | $7.33M | $840.00K | $-2.35M | $-0 |
Net Cash Provided by Operating Activities | $-63.98M | $-46.98M | $-14.33M | $-35 |
Investments in Property Plant and Equipment | $-1.61M | $-1.55M | $-912.00K | $- |
Acquisitions Net | $- | $- | $- | $- |
Purchases of Investments | $- | $- | $-862.50M | $- |
Sales Maturities of Investments | $- | $- | $- | $- |
Other Investing Activities | $- | $- | $862.50M | $- |
Net Cash Used for Investing Activities | $-1.61M | $-1.55M | $-912.00K | $- |
Debt Repayment | $71.00K | $30.95M | $19.07M | $170.00K |
Common Stock Issued | $213.00K | $132.00K | $864.13M | $25.00K |
Common Stock Repurchased | $- | $- | $- | $- |
Dividends Paid | $- | $- | $- | $- |
Other Financing Activities | $95.92M | $-548.00K | $9.87M | $-147.88K |
Net Cash Used Provided by Financing Activities | $95.99M | $30.54M | $28.95M | $47.12K |
Effect of Forex Changes on Cash | $- | $- | $- | $- |
Net Change in Cash | $30.40M | $-17.99M | $13.70M | $47.09K |
Cash at End of Period | $38.42M | $8.02M | $26.02M | $47.09K |
Cash at Beginning of Period | $8.02M | $26.02M | $12.31M | $- |
Operating Cash Flow | $-63.98M | $-46.98M | $-14.33M | $-35 |
Capital Expenditure | $-1.61M | $-1.55M | $-912.00K | $- |
Free Cash Flow | $-65.59M | $-48.53M | $-15.24M | $-35 |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | June 30, 2021 | March 31, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $-9.00M | $-2.16M | $5.59M | $-19.18M | $-21.63M | $-22.00M | $-17.80M | $-12.35M | $-13.57M | $-5.41M | $-6.42M | $2.45M | $-10.69M | $-5.18M |
Depreciation and Amortization | $214.00K | $197.00K | $367.00K | $188.00K | $159.00K | $154.00K | $245.00K | $1.35M | $229.00K | $210.00K | $213.00K | $- | $- | $- |
Deferred Income Tax | $- | $- | $- | $-1.45M | $13.91M | $9.33M | $2.42M | $973.00K | $85.00K | $251.00K | $-34.00K | $- | $- | $- |
Stock Based Compensation | $1.67M | $- | $552.00K | $2.01M | $5.54M | $401.00K | $409.00K | $182.00K | $93.00K | $89.00K | $73.00K | $- | $- | $- |
Change in Working Capital | $-1.97M | $-1.05M | $2.57M | $-3.19M | $-4.51M | $4.00M | $3.89M | $-5.64M | $2.66M | $-7.50M | $-3.31M | $534.80K | $468.87K | $-1.20M |
Accounts Receivables | $2.79M | $2.74M | $1.67M | $2.56M | $-4.81M | $1.36M | $-427.00K | $-8.99M | $-1.68M | $-7.79M | $-4.35M | $- | $- | $- |
Inventory | $-463.00K | $684.00K | $330.00K | $-2.81M | $569.00K | $-1.02M | $-449.00K | $446.00K | $-807.00K | $-357.00K | $-432.00K | $- | $- | $- |
Accounts Payables | $1.93M | $-4.05M | $1.55M | $1.17M | $-1.53M | $-333.00K | $5.35M | $269.00K | $932.00K | $160.00K | $1.96M | $- | $- | $- |
Other Working Capital | $-6.22M | $-423.00K | $-983.00K | $-4.12M | $1.27M | $4.00M | $-590.00K | $2.64M | $4.22M | $487.00K | $-487.00K | $534.80K | $468.87K | $-1.20M |
Other Non Cash Items | $-2.37M | $-5.91M | $-19.98M | $753.00K | $-16.57M | $-1.59M | $526.00K | $-236.00K | $377.00K | $322.00K | $377.00K | $-3.10M | $9.97M | $4.79M |
Net Cash Provided by Operating Activities | $-11.46M | $-8.93M | $-8.64M | $-20.87M | $-23.09M | $-9.70M | $-10.32M | $-15.73M | $-10.13M | $-12.03M | $-9.10M | $-121.78K | $-244.22K | $-1.60M |
Investments in Property Plant and Equipment | $-72.00K | $-435.00K | $-104.00K | $-398.00K | $-800.00K | $-131.00K | $-277.00K | $-459.00K | $157.00K | $-930.00K | $-318.00K | $- | $- | $- |
Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Purchases of Investments | $- | $- | $- | $- | $- | $1.20M | $-1.20M | $- | $- | $- | $- | $-862.50M | $- | $- |
Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Investing Activities | $- | $- | $- | $- | $- | $-1.20M | $1.20M | $776.14M | $- | $- | $- | $862.50M | $- | $-862.50M |
Net Cash Used for Investing Activities | $-72.00K | $-435.00K | $-104.00K | $-398.00K | $-800.00K | $-131.00K | $-277.00K | $-459.00K | $157.00K | $-930.00K | $-318.00K | $- | $- | $-862.50M |
Debt Repayment | $- | $280.00K | $- | $-20.00M | $1.02M | $5.45M | $1.20M | $14.93M | $9.95M | $4.97M | $1.10M | $- | $1.50M | $-264.10K |
Common Stock Issued | $20.93M | $17.00K | $378.00K | $18.00K | $134.00K | $61.00K | $- | $- | $- | $- | $- | $- | $-250.00K | $864.38M |
Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $-776.54M | $- | $- | $- | $- | $- | $- |
Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Financing Activities | $20.93M | $-1.36M | $9.00K | $-426.00K | $97.87M | $-809.00K | $11.67M | $-285.00K | $-162.00K | $-32.00K | $63.00K | $- | $-1 | $- |
Net Cash Used Provided by Financing Activities | $20.93M | $-1.06M | $387.00K | $-20.41M | $98.89M | $4.64M | $12.87M | $14.64M | $9.79M | $4.94M | $1.17M | $- | $1.25M | $864.12M |
Effect of Forex Changes on Cash | $- | $- | $- | $-152.00K | $- | $- | $- | $-1.00K | $- | $1.00K | $- | $- | $- | $- |
Net Change in Cash | $9.79M | $-10.42M | $-8.36M | $-41.83M | $74.99M | $-5.19M | $2.27M | $-1.55M | $-182.00K | $-8.02M | $-8.25M | $-121.78K | $1.01M | $21.19K |
Cash at End of Period | $29.05M | $19.65M | $29.68M | $38.04M | $80.10M | $5.11M | $10.29M | $8.02M | $9.57M | $9.75M | $17.77M | $836.87K | $1.07M | $68.28K |
Cash at Beginning of Period | $19.26M | $30.07M | $38.04M | $79.87M | $5.11M | $10.29M | $8.02M | $9.57M | $9.75M | $17.77M | $26.02M | $958.65K | $68.28K | $47.09K |
Operating Cash Flow | $-11.46M | $-8.93M | $-8.64M | $-20.87M | $-23.09M | $-9.70M | $-10.32M | $-15.73M | $-10.13M | $-12.03M | $-9.10M | $-121.78K | $-244.22K | $-1.60M |
Capital Expenditure | $-72.00K | $-435.00K | $-104.00K | $-398.00K | $-800.00K | $-131.00K | $-277.00K | $-459.00K | $157.00K | $-930.00K | $-318.00K | $- | $- | $- |
Free Cash Flow | $-11.54M | $-9.36M | $-8.74M | $-21.27M | $-23.89M | $-9.83M | $-10.60M | $-16.18M | $-9.97M | $-12.96M | $-9.42M | $-121.78K | $-244.22K | $-1.60M |
Allurion Technologies Stock Forecast
Analyst ratings, price targets, and earnings estimates for ALUR.
ALUR Analyst Ratings
Strong Buy
Based on 2 analysts in the past 3 months
ALUR Stock 12 Month Forecast
$5.00
Based on 1 analysts in the last year
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Apr 04, 2024 | Keay Nakae | Chardan Capital | $5.00 | $1.73 | 189.0% |
Allurion Technologies Dividends
Explore Allurion Technologies's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Medical - Devices
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|
Related Metrics
Explore detailed financial metrics and analysis for ALUR.